Holen Sie sich die Stockscreener-App
81.72
0.83%
-0.68
Handel nachbörslich:
82.01
0.29
+0.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$82.40
Offen:
$81.98
24-Stunden-Volumen:
2.90M
Relative Volume:
0.63
Marktkapitalisierung:
$253.45B
Einnahmen:
$56.53B
Nettoeinkommen (Verlust:
$8.32B
KGV:
30.70
EPS:
2.6622
Netto-Cashflow:
$8.49B
1W Leistung:
-2.78%
1M Leistung:
-4.21%
6M Leistung:
+12.81%
1J Leistung:
+14.42%
1-Tages-Spanne:
$81.05
$82.40
1-Wochen-Bereich:
$81.05
$84.22
52-Wochen-Spanne:
$61.24
$86.57
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
81.72 | 255.48B | 56.53B | 8.32B | 8.49B | 2.6622 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca wins shareholder backing for NYSE listing in US pivot - Reuters
AstraZeneca reports total voting rights at 1.55 billion shares By Investing.com - Investing.com South Africa
AstraZeneca, Merck, Eli Lilly to invest $120M in Virginia pharma manufacturing training center - The Business Journals
AstraZeneca Shareholders Approve Harmonized Listing Structure - MarketScreener
AstraZeneca (AZN) Shareholders Approve New Articles for Equity L - GuruFocus
AstraZeneca wins shareholder approval for New York listing - Financial Times
AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US - MarketScreener
REGAstraZeneca PLCResult of General Meeting - TradingView
Will AstraZeneca PLC (ZEG) stock test record highs in 2025Weekly Investment Recap & Technical Pattern Based Signals - newser.com
What market sentiment indicators show for Precidian ETFs Trust AstraZeneca PLC stockJuly 2025 Weekly Recap & Community Consensus Stock Picks - newser.com
AstraZeneca PLC $AZN Shares Sold by Nicholas Company Inc. - MarketBeat
Will Precidian ETFs Trust AstraZeneca PLC stock hit Wall Street targetsJuly 2025 Earnings & Reliable Entry Point Alerts - newser.com
Will AstraZeneca PLC Depositary Receipt continue its uptrendWall Street Watch & Risk Adjusted Buy/Sell Alerts - newser.com
Cambiar Investors LLC Purchases New Position in AstraZeneca PLC $AZN - MarketBeat
Can AstraZeneca PLC Depositary Receipt stock sustain revenue growthJuly 2025 Movers & Smart Allocation Stock Reports - newser.com
Why AstraZeneca PLC (ZEG) stock stays on top picksEarnings Growth Summary & Expert Curated Trade Setup Alerts - newser.com
AstraZeneca PLC $AZN Shares Sold by iA Global Asset Management Inc. - MarketBeat
Is AstraZeneca PLC (Common Stock) (ZEGA) stock a top pick for value investorsEarnings Risk Report & Detailed Earnings Play Strategies - newser.com
ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer - Clinical Trials Arena
Technical signs of recovery in AstraZeneca PLC Depositary ReceiptLong Setup & Weekly High Return Stock Opportunities - newser.com
Risk vs reward if holding onto AstraZeneca PLC Depositary ReceiptSwing Trade & Real-Time Volume Triggers - newser.com
How moving averages guide AstraZeneca PLC Depositary Receipt tradingMarket Sentiment Report & Real-Time Volume Analysis - newser.com
How AstraZeneca PLC (Common Stock) (ZEGA) stock performs during market turbulence2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
Why ETFs are accumulating AstraZeneca PLC (ZEG) stockMarket Growth Summary & High Accuracy Trade Signal Alerts - newser.com
AstraZeneca PLC Depositary Receipt stock chart pattern explainedWeekly Trade Recap & High Accuracy Trade Alerts - newser.com
AMG National Trust Bank Acquires 32,006 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Atria Investments Inc - MarketBeat
AstraZeneca PLC $AZN Shares Bought by Assetmark Inc. - MarketBeat
Using Python tools to backtest AstraZeneca PLC Depositary Receipt strategies2025 Short Interest & Community Consensus Picks - newser.com
How AstraZeneca PLC Depositary Receipt stock responds to policy changesJuly 2025 Highlights & Risk Controlled Stock Alerts - newser.com
What drives AstraZeneca PLC ZEG stock priceMarket Sentiment Surveys & Optimize Entry & Exit With Smart Signals - earlytimes.in
Using fundamentals and technicals on AstraZeneca PLC Depositary ReceiptInsider Buying & Technical Entry and Exit Tips - newser.com
Will AstraZeneca PLC (ZEG) stock profit from AI boomWeekly Earnings Recap & AI Based Buy/Sell Signal Reports - newser.com
Institutional scanner results for AstraZeneca PLC Depositary ReceiptWeekly Profit Analysis & Consistent Growth Equity Picks - newser.com
Is AstraZeneca PLC Depositary Receipt a good long term investmentWeekly Market Snapshot & Outstanding Portfolio Tips - earlytimes.in
Hantz Financial Services Inc. Boosts Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Responsible care and use of animals in research - AstraZeneca
Annual report 2024 - AstraZeneca
Inclusion and Diversity - AstraZeneca
Healthcare delivery - AstraZeneca
Ethics and Compliance - AstraZeneca
Health Equity - AstraZeneca
AstraZeneca PLC Stock Falls Friday, Outperforms Market - 富途牛牛
AstraZeneca to face questions on Trump MFN deal, patent expiries and pipeline - Proactive financial news
ASTRAZENECA : UBS maintains a Buy rating - MarketScreener
AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win - Clinical Trials Arena
AstraZeneca (AZN) Begins Phase 3 Trial for Enhertu in Lung Cance - GuruFocus
Has AstraZeneca PLC Depositary Receipt formed a bullish divergenceInsider Buying & Safe Capital Allocation Plans - newser.com
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):